Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer

Summary: The FDA just gave a super-fast green light to a drug called Bizengri, which treats a very rare and aggressive bile duct cancer. Usually, it takes up to a year to review a new drug, but thanks to a new "national priority" program, this approval took just a few days! This fast pass is great news for patients who desperately need new options. However, some lawmakers are worried that rushing the process could lead to mistakes or unfair favors. The FDA plans to hold a public meeting soon to talk about these concerns.

Source: rssapp-fiercepharma-com URL: fiercepharma.com/pharma/partners-bispecific-bizengri-nabs-7th-fda-national-priority-nod-rare-bile-duct-cancer (opens in new tab)